Contact
searchSearch
HMP Global
Login

Test- Iclusig CML 2020

Recent News

News
Iberdomide Plus Daratumumab and Dexamethasone Significantly Improves PFS in Relapsed or Refractory Multiple Myeloma
10/08/2026
Stephanie Holland
Topline results from the phase 3 EXCALIBER-RRMM trial demonstrated significantly prolonged progression-free survival with iberdomide plus daratumumab and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in...
Topline results from the phase 3 EXCALIBER-RRMM trial demonstrated significantly prolonged progression-free survival with iberdomide plus daratumumab and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in...
Topline results from the phase 3...
10/08/2026
Oncology
News
Cytarabine Induction Followed by Azacitidine and Lenalidomide Shows Activity in Very-High-Risk Myelodysplastic Syndromes
10/08/2026
Emily Estrada
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study...
10/08/2026
Oncology
News
Acute Myeloid Leukemia Transformation Emerges as Strongest Predictor of Relapse After Allogenic-HSCT in Myelodysplastic Syndromes
10/08/2026
Emily Estrada
A retrospective analysis of patients with myelodysplastic syndromes undergoing allogenic hematopoietic stem cell transplantation identified acute myeloid leukemia transformation as the strongest independent predictor of post-transplant...
A retrospective analysis of patients with myelodysplastic syndromes undergoing allogenic hematopoietic stem cell transplantation identified acute myeloid leukemia transformation as the strongest independent predictor of post-transplant...
A retrospective analysis of...
10/08/2026
Oncology
News
Epcoritamab Plus R-CHOP Improves Progression-Free Survival Over R-CHOP Alone in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma
10/08/2026
Emily Estrada
Topline results from the phase 3 EPCORE DLBCL-2 trial demonstrated that adding epcoritamab to R-CHOP significantly improved progression-free survival in newly diagnosed patients with diffuse large B-cell lymphoma, providing phase 3 evidence...
Topline results from the phase 3 EPCORE DLBCL-2 trial demonstrated that adding epcoritamab to R-CHOP significantly improved progression-free survival in newly diagnosed patients with diffuse large B-cell lymphoma, providing phase 3 evidence...
Topline results from the phase 3...
10/08/2026
Oncology
News
SurVaxM Shows Survival Signal in Newly Diagnosed Glioblastoma, With Significant Benefit in Younger Patients
10/07/2026
Emily Estrada
Results from the phase 2b SURVIVE trial showed a numerical overall survival improvement with SurVaxM in newly diagnosed patients with glioblastoma that did not reach statistical significance, while a prespecified subgroup of patients aged 65...
Results from the phase 2b SURVIVE trial showed a numerical overall survival improvement with SurVaxM in newly diagnosed patients with glioblastoma that did not reach statistical significance, while a prespecified subgroup of patients aged 65...
Results from the phase 2b...
10/07/2026
Oncology
FDA Approval
FDA Approves Tucatinib Plus Trastuzumab and Pertuzumab for Maintenance Treatment of HER2-Positive Advanced Breast Cancer
10/07/2026
Stephanie Holland
Based on results from the HER2CLIMB-05 trial, the FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance treatment for HER2-positive advanced breast cancer following induction therapy, establishing a new maintenance option...
Based on results from the HER2CLIMB-05 trial, the FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance treatment for HER2-positive advanced breast cancer following induction therapy, establishing a new maintenance option...
Based on results from the...
10/07/2026
Oncology
FDA Approval
FDA Expands Pirtobrutinib to First-Line Treatment of CLL/SLL Without 17p Deletion
10/02/2026
Stephanie Holland
Based on results from BRUIN CLL-313, the FDA approved pirtobrutinib for previously untreated CLL/SLL without a known 17p deletion, establishing a first-line treatment option supported by a significant progression-free survival benefit over...
Based on results from BRUIN CLL-313, the FDA approved pirtobrutinib for previously untreated CLL/SLL without a known 17p deletion, establishing a first-line treatment option supported by a significant progression-free survival benefit over...
Based on results from BRUIN...
10/02/2026
Oncology
News
Risvutatug Rezetecan More Than Doubles Response and Significantly Extends Survival in Patients With Relapsed Small Cell Lung Cancer
09/29/2026
Emily Estrada
Results from the phase 3 ARTEMIS-008 trial demonstrated that risvutatug rezetecan significantly improved overall and progression-free survival and response outcomes compared with topotecan in patients with small cell lung cancer who...
Results from the phase 3 ARTEMIS-008 trial demonstrated that risvutatug rezetecan significantly improved overall and progression-free survival and response outcomes compared with topotecan in patients with small cell lung cancer who...
Results from the phase 3...
09/29/2026
Oncology
News
Tambotatug Pelitecan Significantly Improves Survival Over Topotecan in Patients With Relapsed Small Cell Lung Cancer
09/27/2026
Emily Estrada
Results from the phase 3 TAISHAN-302 study demonstrated that tambotatug pelitecan significantly improved overall and progression-free survival compared with topotecan in patients with relapsed small cell lung cancer, supporting the...
Results from the phase 3 TAISHAN-302 study demonstrated that tambotatug pelitecan significantly improved overall and progression-free survival compared with topotecan in patients with relapsed small cell lung cancer, supporting the...
Results from the phase 3...
09/27/2026
Oncology
FDA Approval
FDA Approves Belzutifan Plus Lenvatinib Following Immunotherapy in Advanced Clear Cell Renal Cell Carcinoma
09/24/2026
Emily Estrada
Based on results from the LITESPARK-011 trial, the FDA has approved belzutifan plus lenvatinib following PD-1 or PD-L1 inhibitor therapy for patients with advanced clear cell renal cell carcinoma, providing a new combination treatment option...
Based on results from the LITESPARK-011 trial, the FDA has approved belzutifan plus lenvatinib following PD-1 or PD-L1 inhibitor therapy for patients with advanced clear cell renal cell carcinoma, providing a new combination treatment option...
Based on results from the...
09/24/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use